GemPharmatech Co

GemPharmatech Co OCF/Debt

The Operating Cash Flow to Debt Ratio of GemPharmatech Co (688046.SS) as of Oct 22, 2026 is 565.80 %. In the previous year, Operating Cash Flow to Debt Ratio was 2,170.69 % — a change of -73.93% (lower).

OCF/Debt

565.80 %

YoY

-73.93%

Last updated:

Operating Cash Flow to Debt Ratio of GemPharmatech Co is 2021 565.80 % . Operating Cash Flow to Debt Ratio of GemPharmatech Co was 2020 2,170.69 % . It decreases by -73.93% lower compared to the previous year.

The GemPharmatech Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
2,170.69 CNY
Jan 1, 2021
565.80 CNY
The GemPharmatech Co OCF/Debt history
YEAROCF/DebtYoY
565.80 %-73.93%
2,170.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GemPharmatech Co Stock analysis

What does GemPharmatech Co do? GemPharmatech Co., Ltd. generates revenue through the research and development, manufacturing, and sale of experimental mouse models. The company utilizes gene-editing and other technologies to produce these models, which are primarily sold to satisfy experimental demands in gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental research areas. Customized model breeding, drug efficacy analysis, and model customization services are also key revenue streams, targeting institutions engaged in biomedical research and pharmaceutical development. The company's products and services are tailored for clients in the fields of gene function cognition, disease mechanisms analysis, and drug target discovery. These clients include research institutions and pharmaceutical companies requiring specialized mouse models for preclinical studies and drug development. The firm's focus on gene-editing technologies enables it to provide high-quality, customized solutions that meet specific research needs. GemPharmatech's business model centers on providing innovative solutions for experimental research through its proprietary gene-editing technologies. By offering both standard and customized mouse models alongside related services, the company addresses the growing demand for precise and efficient research tools in the pharmaceutical and biotechnology sectors. The firm's revenue streams are directly tied to the sale of these models and the provision of specialized services to clients in the biomedical research industry. GemPharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GemPharmatech Co stock

Operating Cash Flow to Debt Ratio of GemPharmatech Co is 565.80 % in 2021.

Operating Cash Flow to Debt Ratio of GemPharmatech Co changed from 2,170.69 % to 565.80 %, representing a -73.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio GemPharmatech Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's GemPharmatech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — GemPharmatech Co

All Key Metrics — GemPharmatech Co